Keryx to Present at Rodman & Renshaw Techvest Conference

    Keryx Biopharmaceuticals to Present at Rodman & Renshaw Techvest Healthcare 
                                  Conference 
  
    NEW YORK, Oct. 16 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX, London 
AIM: KRX), a biopharmaceutical company focused on the acquisition, development 
and commercialization of novel pharmaceutical products for the treatment of 
life-threatening diseases, including diabetes and cancer, announced today that 
Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview 
of the Company's strategic plans and progress with its lead drug candidate, KRX-
101, at the Rodman & Renshaw Techvest Healthcare Conference in Boston.  Mr. 
Weiss's presentation will take place on Tuesday, October 21, 2003, at 12:40pm 
EST, in Salons J-L of the Boston Marriott Long Wharf Hotel.  A live audio 
webcast will be available during the presentation at        
http://www.wallstreetwebcasting.com/webcast/rrshq/kerx/
and will be archived for a period of 60 days.  
 
    About Keryx Biopharmaceuticals, Inc.  
    Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; London AIM: KRX) is a 
biopharmaceutical company focused on the acquisition, development and 
commercialization of novel pharmaceutical products for the treatment of  
life-threatening diseases, including diabetes and cancer.  Keryx is developing 
KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound, for the 
treatment of diabetic nephropathy, for which Keryx is currently planning its 
U.S.-based Phase II/III clinical program. Keryx also has an active  
in-licensing program designed to identify and acquire clinical-stage drug 
candidates.  Additionally, Keryx is seeking partners for its KinAce(TM) drug 
discovery technology and related products.  Keryx Biopharmaceuticals is 
headquartered in New York City.  
 
     KERYX CONTACT: 
     Ron Bentsur 
     VP Finance and Investor Relations 
     Keryx Biopharmaceuticals, Inc. 
     Tel: [phone] 
     E-mail: [e-mail] 
 
SOURCE  Keryx Biopharmaceuticals, Inc.  
    -0-                             10/16/2003 
    /CONTACT:  Ron Bentsur, VP Finance and Investor Relations of Keryx 
Biopharmaceuticals, Inc., [phone], [e-mail]/ 
    
    /Web site:  http://www.wallstreetwebcasting.com/webcast/rrshq/kerx/ 
    (KERX) 
 





END